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Monozygotic twins affected with major depressive
disorder have greater variance in methylation than
their unaffected co-twin
EM Byrne1,4, T Carrillo-Roa2,4, AK Henders2, L Bowdler2, AF McRae1,2, AC Heath3, NG Martin2, GW Montgomery2, L Krause2,5 and
NR Wray1,5

Our understanding of major depressive disorder (MDD) has focused on the influence of genetic variation and environmental risk
factors. Growing evidence suggests the additional role of epigenetic mechanisms influencing susceptibility for complex traits.
DNA sequence within discordant monozygotic twin (MZT) pairs is virtually identical; thus, they represent a powerful design for
studying the contribution of epigenetic factors to disease liability. The aim of this study was to investigate whether specific
methylation profiles in white blood cells could contribute to the aetiology of MDD. Participants were drawn from the Queensland
Twin Registry and comprised 12 MZT pairs discordant for MDD and 12 MZT pairs concordant for no MDD and low neuroticism.
Bisulphite treatment and genome-wide interrogation of differentially methylated CpG sites using the Illumina Human Methylation
450 BeadChip were performed in WBC-derived DNA. No overall difference in mean global methylation between cases and their
unaffected co-twins was found; however, the differences in females was significant (P ¼ 0.005). The difference in variance across
all probes between affected and unaffected twins was highly significant (Po2.2  10  16), with 52.4% of probes having higher
variance in cases (binomial P-valueo2.2  10  16). No significant differences in methylation were observed between discordant
MZT pairs and their matched concordant MZT (permutation minimum P ¼ 0.11) at any individual probe. Larger samples are likely
to be needed to identify true associations between methylation differences at specific CpG sites.
Translational Psychiatry (2013) 3, e269; doi:10.1038/tp.2013.45; published online 11 June 2013
Introduction
Major depressive disorder (MDD) is a complex disorder with a
considerable impact on the quality of patient’s lives1 including
an increased rate of mortality.2,3 Lifetime prevalence is
estimated to be 15% and it is twice more common in women
than in men.2,4 Heritability of MDD is estimated to be B40%.5
There have been no common genetic variants convincingly
associated with MDD,6 and most of the variants identified for
complex psychiatric disorders contribute to a small fraction of
the genetic variation and explain only a small proportion of
the heritability.7 Growing evidence suggests that variations in
epigenetic profiles (that is, DNA methylation) influence
complex trait variation.8 Epigenetic modifications do not
directly interfere with the gene transcript but control tissue
and temporal specificity of gene expression.9,10 DNA methylation is the most common epigenetic variation in the
mammalian genome8 and is not entirely stable; stochastic
and environmental events can also generate variations over
time.11 Non-heritable influences on depression may mediate
their biological effects through epigenetic mechanisms such
as methylation of CpG dinucleotides.
Several epigenetic studies have attempted to identify
differences in DNA methylation associated with complex
traits. Associations between variations in DNA methylation
1

profiles and various psychiatric disorders (for example,
schizophrenia, MDD, bipolar disorder and so on) have been
reported.12–17 Some limitations should be considered from
these studies (for example, small samples sizes, sample
heterogeneity, epigenome coverage). Tissues involved in
complex psychiatric disorders are not directly accessible from
living patients; epigenetic studies often rely on peripheral
tissue biomarkers such as buccal, gut and white blood cells
(WBC).18 Post-mortem tissue can also be used in epigenetic
studies to compare central and peripheral tissue;19 however,
samples are not easily accessible. Moreover, post-mortem
epigenetic measures may reflect treatment rather than
disease. More research is needed to determine the accuracy
of peripheral tissue biomarkers.19
Discordant monozygotic twin (MZT) pairs constitute a
powerful design in epigenetic studies.20,21 Single-nucleotide
polymorphisms and other DNA sequence variations, which
are abundant in singleton-based studies, are not a confounding source of variation in MZT-based epigenetic studies.
The aim of our study was to examine whether diverse
epigenetic profiles, specifically DNA methylation profiles, are
associated with increased risk of MDD. We analysed genomewide methylation patterns after bisulphite conversion of CpG
sites using the Illumina Human Methylation (HM) 450
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BeadChip (HM 450 BeadChip) of WBC-derived DNA from
12 discordant MZT (6 male and 6 female) pairs and
24 concordant MZT pairs.
Materials and methods
Sample selection/study design. Participants were drawn
from the Queensland Twin Registry. Phenotypic information
was collected as part of studies undertaken at the Queensland Institute of Medical Research each approved by the
Institute’s ethics committee. On the basis of the study,
depressive symptoms were evaluated with either the SemiStructured Assessment for the Genetics of Alcoholism,22
(adapted for use in Australia) or the Composite International
Diagnostic Interview23 questionnaires. A diagnosis of MDD
was constructed from these questionnaires according to the
Diagnostic and Statistical Manual of Mental Disorders-IV
criteria.24 A total of 17 958 individuals from 6855 families
have completed psychiatric interviews, including a total of
1812 MZT pairs, of whom 261 were found to be discordant
for MDD.
Six MZT female pairs (including five MZT female pairs
previously epityped with the Illumina HM 27 BeadChip;
Illumina, San Diego, CA, USA) and six MZT male pairs
discordant for MDD were selected as ‘case pairs’. Where
possible, we selected case probands with (the more severe)
recurrent MDD; all six MZT females and two of the six males
met this criterion. Further, we aimed to select twins who were
recorded as non-smokers and not alcohol or drug dependent,
criteria that imposed severe restrictions on MZT selection,
and so selection criteria were extended to include MZT that
were matched for these criteria (for example, both smokers
with similar daily consumption and age of initiation). Six MZT
female pairs and six MZT male pairs concordant for no MDD
and low neuroticism were selected as ‘control pairs’. Neuroticism is a domain of personality easily measured by self-report.
High neuroticism scores are associated with anxiety and
depression; therefore, low scores are expected to represent
those with a low liability for depression.25 This gives our study
more power to detect variations in methylation status
associated with MDD. Environmental factors such as smoking, alcohol or drug abuse are associated with altered
methylation patterns.26,27 Each concordant MZT pair was
selected to match as closely as possible to a discordant MZT
pair on a number of key variables (Supplementary Tables 1
and 2). Matching criteria were date of blood sample collection,
(as methylation differences increase with age20,25) smoking
and alcohol as well as previous history of drug use. A total of
24 MZT pairs (48 individuals) were selected for our study
(Table 1). All individuals were of Northern European ancestry.

Bisulphite conversions. Bisulphite conversions of previously extracted WBC-derived DNA from the 48 individuals,
6 technical replicate samples and technical control samples
(described below) were performed following the protocol and
using reagents of the EZ DNA methylation Kit (Zymo
Research, Irvine, CA, USA). Each conversion included 10
samples and DNA recovery after conversion was quantified
using Nanodrop (Thermo Scientific, Wilmington, DE, USA).
In total, eight bisulphite conversions were undertaken, each
comprising three to four MZT pairs, technical replicates
and control samples. Later runs repeated eight MZT pairs
that had generated o80% DNA recovery in earlier runs
(Supplementary Table 3).
Technical controls consisted of commercial DNA samples:
Centre Etude Polymorphism Humain (CEPH) male
(GM07029), CEPH female (GM06997) and FSK standard
(Coriell Institute of Medical Research, Camden, NJ, USA).
DNA recovery for the CEPH female sample after bisulphite
conversion was B50%; for this reason the CEPH male and
the FSK standard were included in the later bisulphite
conversions (Supplementary Table 3). Only FSK standard
samples were included in the HM 450 BeadChips as controls
because of their high percentage recovery of the bisulphiteconverted DNA.
Infinium methylation assay. Bisulphite-converted DNA
from 24 MZT pairs, 4 technical replicate samples and 4
FSK standard controls were hybridised to the Illumina HM
450 BeadChip, following the Illumina Infinium HD methylation
protocol and using reagents and conditions supplied by
Illumina. The HM 450 BeadChip-assessed methylation
status was interrogated at 485 577 CpG sites across the
genome. It provides coverage of 99% of RefSeq genes.
Methylation scores for each CpG site are obtained as a ratio
of the intensities of fluorescent signals and are represented
as b-values.
maxM
b  value ¼
ðmaxM þ maxU þ 100Þ
where max ¼ maximum intensity of fluorescence, M ¼
methylated allele and U ¼ unmethylated allele.28 The 100 in
the denominator prevents division by 0 when both max M and
max U are very small, but has little impact otherwise as max
M þ max U41000 in 495% of sites.29 b-values range
between 0 and 1, where 0 means that no DNA molecules
with a methylated CpG at the site of interest were detected in
the sample, while 1 means that all DNA molecules had a
methylated CpG site in the sample.
Each MZT pair was placed on the same array and in
neighbouring wells to avoid batch effects contributing to

Table 1 Summary of cases and controls

Cases

Controls

6 (5 þ 1) MZT ~ pairs discordant for MDD
6 MZT # pairs discordant for MDD
Total 24 MZT discordant for MDD

6 MZT ~ pairs concordant for no MDD and low neuroticism
6 MZT # pairs concordant for no MDD and low neuroticism
Total 24 MZT concordant for no MDD and low neuroticism

Abbreviations: MDD, major depressive disorder; MZT, monozygotic twin.
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differences between pairs. A total of five HM 450 BeadChips
were used for this study. Two of the replicate samples were
placed on the same array in non-adjacent wells from the
corresponding MZT whereas the other two replicate samples
were placed on different arrays (Supplementary Table 4). The
FSK male and female samples were also duplicated and placed
on different chips. A total of 56 samples were included in the
arrays. Arrays were scanned with the Illumina iScan (Software
Version 3.3.28) and the intensities of the images were extracted
using the GenomeStudio (2010.3) methylation module (1.8.5)
software.

Table 2 HM 450 BeadChip distribution of probes

Quality control. Background was subtracted from our data
using GenomeStudio (2010.3). Illumina’s specification for the
HM 450 BeadChip is 98% detection of CpG with Po0.05.
All of our samples included in the five BeadChips exceeded
specification, with 499% of CpG loci detected; therefore, no
samples were excluded from the study. Three hundred
seventy-three probes for which 75% of the samples had a
detection P-value40.05 were removed. A total of 485 204
probes remained.
The b-values were transformed using a logit transformation
in the IMA30 package in the R environment for statistical
computing (version 2.13.2); http://www.R-project.org). Transforming via a logit transformation increases the validity of
statistical tests of differential methylation.29 Supplementary
Figure 1 shows a histogram of the transformed b-values
across all samples. The peak correction method of Deuderwaerder et al.31 was applied to correct for differences in
results between the two chemistries utilised on the HM 450
chip. QC plots produced by the IMA package are shown in
Supplementary Figures 2–4. Unsupervised clustering of all
samples showed that male and female samples clustered
together. Furthermore, replicate samples and twin samples
clustered together providing an indication of the accuracy of
the methylation detection procedure.
To improve the accuracy of our results, we excluded
potential sources of technical and biological biases before
analysing the methylation data. There is currently no standard
procedure for filtering the samples and probes before
methylation analysis.32 Our experimental design, including
replicate samples enabled stringent quality control (QC)
steps. These QC steps are described in detail in the
Supplementary Methods. The number of sites annotated by
probe type that were removed by the QC steps are shown in
Table 2. After removing probes with large amounts of missing
data and high levels of discordance between replicate pairs, a
total of 462 002 (95.1%) probes remained for analysis.

methylation between monozygotic co-twins owing to MDD, a
linear model was fitted. For each probe, the absolute
difference between each twin pair was taken and regressed
on matched twin set and case–control status.

Statistical analysis. A two-sample t-test was used to test
for differences in overall mean methylation between monozygotic cases and their unaffected co-twin. In order to test for
differences in variance between cases and their unaffected
co-twin, the variance for each probe was computed in cases
and their unaffected co-twin separately, and the distributions
were compared using the Wilcoxon signed-rank test. All
statistical tests were implemented in R.
Testing for differences between MZTs owing to MDD at
each individual probe. In order to test for differences in

Annotation
Island
Shelf
Shore
NCpG
Total

Before QC

QC1

QC2

150 254
47 161
112 072
176 277
485 557

143 391
46 447
109 736
172 695
472 269

138 738
45 691
107 394
170 178
462 001

Abbreviations: HM, human methylation; QC, quality control.
QC1 represents remaining probes after QC1. QC2 represents remaining
probes after QC2.

yijk1  yijk2 ¼ Seti þ MDDj þ eijk
where, yijkl ¼ the residual transformed b-value of a probe
after adjusting for batch and chip effects of the lth (l ¼ 1,2)
twin of the jth twin pair (j ¼ 1,2) from the ith set (i ¼ 1,..,12).
MDDj is an indicator such that MDDj ¼ 1 for the discordant
pairs and MDDj ¼ 0 for the concordant pair eijk is the random
error term. By taking the absolute difference in the residuals
of the transformed b-value between MZT, the test can reflect
both probes that are associated with more or less methylation or probes that are more variably methylated probes
associated with MDD. Under the MZT design we assume that
any confounding variables are independent of the differences
between MZT.
To establish the significance of the top results, a set of 100
permutations were performed. In each permutation, the
concordant pair and discordant label were randomly assigned
within each twin pair set, the analysis was performed for each
probe, and the P-value for case–control status was extracted.
The results of each permutation were extracted and ranked.
The mean of the P-values with the same rank across all 100
permutations was calculated and the distribution of the means
was taken as the null distribution. An empirical P-value was
calculated by counting the proportion of permutations that had
at least one probe more significant than the top probe
identified in the real data set.
Pathway analysis. All genes for which at least one probe
had a P-valueo0.001 for association with MDD status were
uploaded to the commercial pathway analysis software
Ingenuity Pathway Analysis (Ingenuity Systems, Redwood
City, CA, USA) and the freely available software DAVID,33 to
test for enrichment of associations in functional pathways
and gene ontology terms.
Results
Global differences in mean and variance. There was no
significant difference in overall methylation between discordant pairs (P ¼ 0.56). As there were highly significant differences in overall methylation of autosomal probes between
males and females (Po2.2  10  16; Supplementary
Material) as previously reported by others,34,35 we tested
for differences in overall methylation levels by sex within
Translational Psychiatry
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discordant pairs. The difference in mean methylation was
not significant (P ¼ 0.05), but was significant in females
(P ¼ 0.005), with cases being less methylated when compared with controls (whereas the trend of differences in
males was the opposite).
The difference in variance between cases and their control
co-twins was highly significant (Po2.2  10  16), with 52.4%
of probes having higher variance in cases (binomial P-value
2.2  10  16). This increased variance in cases was consistent across all annotated probe types (Supplementary
Table 6). The result was significant in males and females
(both Po2.2  10  16). A jackknifing procedure where one
twin pair was removed and the data reanalysed also gave
significant results across all 12 replicates, indicating that the
significant results are not attributable to one specific pair.
The mean of the probe variances was 0.09 with s.d. 0.27
with range 0.001–10.54. The distribution was highly skewed
(Supplementary Figures 6a and b), with the majority of probes
having a small variance compared with a much smaller
number of probes that are highly variable. In order to test
whether there were differences in the distribution of variances
between cases and controls in probes with both high and low
overall variance, we subdivided the probes into deciles based
on their variance. We then performed the Wilcoxon signed-

Table 3 Results from comparing distribution of variances in cases and controls
by decile

Decile

Wilcoxon
signed-rank test
P-value

Proportion of probes
with increased
variance in cases

1
2
3
4
5
6
7
8
9
10

o2.2  10E  16
o2.2  10E  16
o2.2  10E  16
o2.2  10E  16
o2.2  10E  16
o2.2  10E  16
o2.2  10E  16
6.50E  04
8.79E  01
1.25E  04

0.545
0.539
0.539
0.530
0.531
0.522
0.519
0.508
0.501
0.504

rank test for differences in variance in each of the probe sets.
Across all of the deciles, more than half of the probes had a
higher variance in cases than in controls. The differences in
variance were significant in each of the deciles except for the
ninth (Table 3).
In order to test whether the differences in variance could be
attributed to use of antidepressants, we tested for differences
in variances between cases who had been prescribed
antidepressants (n ¼ 6) and their co-twin control, and separately for cases who had not been prescribed antidepressants
(n ¼ 6) and their co-twin. Cases who had been prescribed
antidepressants had increased variance at 51.5% of
probes and the difference in variances was highly significant
(Po2.2  10  16). Cases that had not been prescribed
antidepressants had increased variance relative to their
unaffected co-twins at 51.4% of probes and the difference in
variances was highly significant (Po2.2  10  16).
MDD discordance at individual probes. The QQ plot for
the genome-wide methylation analysis of concordant and
discordant twins is shown in Supplementary Figure 5a. The
observed distribution of P-values for the probes did not
deviate from null distribution. The most significant probe was
cg15083522 (P ¼ 1.38  10  6, Table 4), found on chromosome 10 in a CpG island upstream of the MAST4 gene. This
probe was not significant when compared against the null
distribution of all probes (P ¼ 0.11) or when compared with all
probes in shores (P ¼ 0.06) (Supplementary Figures 5b–d).
The MAST4 gene is expressed in a distinct pattern in white
matter-containing regions of the brain in rodents.36 Other
members of the MAST family have been implicated in
dopaminergic signalling in dendrites.37 However, this gene
has not previously been linked to MDD or other mood
disorders.
Among the genes that harbour probes that are most
significantly differentiated between discordant pairs, MAD1L1
is the only gene that has been previously implicated in the
aetiology of mood disorders. The 3rd most significant probe
was located in the MAD1L1 gene (cg08985282, P ¼ 2.16
 10  5, Table 4). Recently, two independent genome-wide

Table 4 Probes that are most significantly differentiated between discordant and concordant pairs (Po10  4)

ILMNID
cg10665379
cg17222196
cg08985282
cg25372357
cg22864266
cg10946423
cg11843516
cg22374165
cg22231758
cg14852276
cg00270520
cg06339265
cg04145601
cg09858767
cg22618878
cg07048516
cg03666973
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CHR

MAPINFO

UCSC_REFGENE_NAME

UCSC_REFGENE_
ACCESSION

RELATION_TO_
UCSC_CPG_ISLAND

5
1
7
4
12
20
1
2
17
3
2
16
20
1
6
22
2

65891878
155057324
2089600
56659770
49319673
44565633
17023283
39199173
69199815
197684729
241579262
11369615
44641469
14742375
27156656
24105087
27008764

MAST4
EFNA3
MAD1L1
NA
FKBP11
PCIF1
ESPNP
LOC100271715
NA
IQCG
NA
PRM2
MMP9
NA
NA
C22orf15
CENPA

TSS1500
Body
Body
NA
TSS1500
5’UTR
Body
3’UTR
NA
5’UTR
NA
3’UTR
Body
NA
NA
TSS200
TSS200

Island
Island
Island
Island
S_Shore
S_Shore
Island
NA
NA
N_Shelf
N_Shore
N_Shore
N_Shore
NA
NA
NA
Island

P-value
1.38E  06
1.89E  05
2.16E  05
2.59E  05
2.68E  05
2.98E  05
3.19E  05
3.65E  05
3.93E  05
4.37E  05
4.54E  05
5.76E  05
5.98E  05
8.21E  05
8.28E  05
9.08E  05
9.48E  05
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significant hits for schizophrenia in this gene were found,38
and evidence of association with bipolar disorder was found in
a recent meta-analysis (rs4332037, P ¼ 6.3  10  6).39
A total of 211 genes were uploaded to Ingenuity and DAVID
pathway analysis packages. Neither pathway analysis package identified any canonical pathways or biological functions
to be significantly enriched after setting a false discovery
rate of 5%.
Discussion
Previous studies involving MZT pairs discordant for psychiatric disorders have been limited to a small number of twin pairs
(for example, two MZT pairs for schizophrenia40), or have
assessed only a fraction of the genome-wide CpG sites.15,16
This study represents the largest twin study to date of
genome-wide associated methylation differences in MZT
pairs discordant for MDD. Furthermore, this is one of the first
methylation studies in psychiatry that utilises the HM 450
Beadchip, which provides coverage of a much larger number
of CpG sites throughout the genome.
Our analyses included sets of discordant MZT pairs and its
matched concordant pairs. Although our sample size was not
sufficient to identify methylation differences that could be
attributed to MDD, it revealed that cases show a highly
significantly increased variation in methylation throughout the
genome (Po2.2  10  16) when compared with their control
co-twins. This finding suggests that the methylome in patients
with MDD may be undergoing more changes as a result of
environmental influences than that in controls as a result of a
loss of epigenetic stability. Increased variability of methylation
in cases is seen across many cancers,41 but has not been
previously investigated in studies of psychiatric disorders.
One potential reason for this increased variance in cases may
be due to various forms of treatment including the use of
medications such as antidepressants by affected twins that
are not used by the unaffected twins. However, the result
remained significant when comparing those reporting antidepressant use with their co-twins and also in those reporting
no antidepressant use. No information was collected on the
length of time that the drugs were used for or the dosage that
was prescribed. Antidepressant drugs are known to induce
epigenetic changes in the brain42 and may also do so in
blood samples.
Our results also showed that female cases had significantly
increased methylation throughout the genome when compared with their unaffected co-twin (P ¼ 0.005). This significant difference was not detected when comparing male cases
with their unaffected co-twins or when analysing males and
females together. We detected distinct patterns of methylation
in male and female twins across a large number of autosomal
probes, which suggests that analysing methylation differences across the genome by sex is appropriate.
There are a number of important limitations of the design
and analysis of this study. First, the tissue available for
methylation analysis in this study imposes limitations.
Methylation levels are known to vary among tissues.13 Brain
tissue would be the tissue of choice for the study of psychiatric
disorders. However, biopsy is not an option and there is no
available collection of post-mortem MZT brain tissue

discordant for psychiatric disorders.43 For epigenetic studies
of disorders related to neurodevelopment, it has been argued
that cells that are derived from the same embryonic origin as
the cells involved in the disease should be studied;8 for
example, buccal cells have the same embryonic origin as
brain cells. This argument is relevant for psychiatric disorders
like schizophrenia where interest may focus on neurodevelopment. However, if environmental stresses influencing the
liability of MDD occur after the early stages of development
(for example, childhood trauma), then cells from the same
embryonic origin as brain tissue (that is, buccal cells) seem no
more relevant than WBC. Reliance on DNA from WBC means
that the inferences that can be made regarding pathways
involving the brain are limited. However, disease-related
pathways can still be identified from peripheral tissues.43 DNA
methylation differences identified using peripheral tissue may
not be explanatory or causal of changes in gene expression
taking place in the brain, but they could be used as a
diagnostic tool.
A second important limitation of our study is the small
sample size. The discordant MZT model is considered to be
powerful for detecting epigenetic differences21 because the
cases and controls are matched on their genetic complement
eliminating this as a confounding variable. In order to
eliminate confounding environmental risk factors, we imposed
stringent criteria on the selection of MZT. Only a small number
of MZT pairs fulfilled these criteria despite selection from one
of the largest twin collections worldwide. Larger samples
can only be achieved through international consortia or
through relaxation of the selection criteria.
A third limitation of our study was the variability between
samples in factors that may affect methylation. For example,
first, the age of the subjects ranged from 31 to 63 (but was not
significantly different between the sexes). Second, although it
is estimated that 96% of the participants in the Queensland
Institute of Medical Research studies have North European
ancestry,44 ancestry differences between twin pairs cannot be
excluded. Third, environmental factors (that is, alcohol abuse
and smoking) are associated with altered DNA methylation
patterns. We matched pairs as closely as possible; however,
some of the individuals in our sample were smokers or alcohol
dependent. These examples show confounding factors, which
may influence our results especially because our sample size
is small. Future studies would ideally control for these and
other confounding factors.
Another limitation of our design of this study is that blood
samples were collected after the onset of depression. Therefore, any differences in methylation associated between
MZTs associated with MDD may reflect a range of factors
including treatment. A prospective study design, in which
samples are taken before first onset of MDD and then after
disease onset, but before treatment would aid in the
identification of epigenetic biomarkers associated with MDD.
Further collection of samples collected during and after
treatment may also help implicate sites that show the greatest
changes in methylation after successful treatment of the
disorder.
The genetic architecture of complex traits is very heterogeneous. Genome-wide association studies have been
successful in identifying susceptibility variants for complex
Translational Psychiatry
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traits.45 However, most of the variants identified have very
small effect sizes. It is likely that DNA methylation differences
involved in complex psychiatric disorders will also have small
effects, and that sample sizes commensurate with those
utilised in genome-wide association studies may be required
to detect methylation differences at individual CpG islands.
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